Graft-versus-Host Disease Prophylaxis with Post Transplant Cyclophosphamide in Chronic Myeloid Leukemia patients undergoing Allogeneic Hematopoietic Cell Transplant from either an Unrelated or Mismatched Related Donor: a comparative study from the Chr....

[1]  M. Robin,et al.  Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT , 2022, American journal of hematology.

[2]  Y. Natkunam,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.

[3]  N. Kröger,et al.  Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT , 2021, Journal of Hematology & Oncology.

[4]  N. Kröger,et al.  Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years , 2021, Bone Marrow Transplantation.

[5]  K. Gregory,et al.  Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  A. Ganser,et al.  Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. , 2020, Blood advances.

[7]  M. Labopin,et al.  Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT , 2020, Journal of Hematology & Oncology.

[8]  C. Schiffer,et al.  European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia , 2020, Leukemia.

[9]  S. Pileri,et al.  Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study. , 2019, Blood.

[10]  S. Mustjoki,et al.  Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia , 2019, Leukemia.

[11]  U. Popat,et al.  Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. , 2018, Blood advances.

[12]  H. Kantarjian,et al.  Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. , 2016, Blood.

[13]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[14]  R. Vij,et al.  Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. , 2015, Blood.

[15]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[16]  Richard J. Jones,et al.  Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  J. Cayuela,et al.  First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia , 2012, Leukemia.

[18]  J. Klein,et al.  Analysis of non-HLA genomic risk factors in HLA-matched unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia , 2012, Haematologica.

[19]  J. Radich.  Allogeneic transplant for chronic myeloid leukemia in 2010 , 2010, Therapeutic advances in hematology.

[20]  J. Radich,et al.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[22]  A. Nademanee,et al.  HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. Kolb.  Graft-versus-leukemia effects of transplantation and donor lymphocytes. , 2008, Blood.

[24]  M. Maris,et al.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  Allen R. Chen,et al.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  M. Sorror,et al.  Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation , 2008, Cancer.

[27]  Harriet Noreen,et al.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. , 2007, Blood.

[28]  H. Kantarjian,et al.  Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. , 2006, Blood.

[29]  P. Lachenbruch,et al.  Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  J. Wagner,et al.  Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  C. Craddock,et al.  Cytomegalovirus seropositivity adversely influences outcome after T‐depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft‐versus‐host disease prophylaxis , 2001, British journal of haematology.

[32]  A. Nademanee,et al.  Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. , 2000, Blood.

[33]  J. Ritz,et al.  Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J Hermans,et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.

[35]  D. Porter,et al.  International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  Daniel Wolff,et al.  Measuring Therapeutic Response in Chronic Graft-versus-host-disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus- Host Disease: Iv. Response Criteria Working Group Report , 2022 .